Show simple item record

dc.contributor.authorElcioglu, Omer H.
dc.contributor.authorKaran, Mehmet Akif
dc.contributor.authorTufan, Fatih
dc.contributor.authorSolakoglu, Seyhun
dc.contributor.authorKotil, Tugba
dc.contributor.authorELÇİOĞLU, HATİCE KÜBRA
dc.contributor.authorKABASAKAL, LEVENT
dc.date.accessioned2021-03-05T17:59:09Z
dc.date.available2021-03-05T17:59:09Z
dc.date.issued2015
dc.identifier.citationELÇİOĞLU H. K. , KABASAKAL L., Tufan F., Elcioglu O. H. , Solakoglu S., Kotil T., Karan M. A. , "Effects of systemic Thalidomide and intracerebroventricular Etanercept and Infliximab administration in a Streptozotocin induced dementia model in rats", ACTA HISTOCHEMICA, cilt.117, ss.176-181, 2015
dc.identifier.issn0065-1281
dc.identifier.otherav_c82c5274-8bc6-4cfd-82cd-4dc8600d52ca
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/132656
dc.identifier.urihttps://doi.org/10.1016/j.acthis.2014.12.002
dc.description.abstractTumor necrosis factor-alpha (TNF-alpha) upregulation enhances amyloid beta (AP beta) induced neurotoxicity in Alzheimer's disease (AD). Intracerebroventricular streptozotocin (STZ) administration causes pathological changes and cognitive deficits similar to those seen in AD by causing impairment of brain glucose and energy metabolism. Recent reports indicate a protective role of Thalidomide. Etanercept, and Infliximab, all of which have anti-TNF-alpha activity, against cognitive and neuropathological changes in experimental and clinical studies. We aimed to investigate the protective effects of Thalidomide, Etanercept, and Infliximab in a rat model of intracerebroventricular STZ-induced dementia. Sprague-Dawley rats (250-300 g) were separated to sham (n = 6) and STZ (n = 24) groups. The STZ group was divided into four groups (STZ, STZ-thalidomide, STZ-etanercept, and STZ-infliximab). Morris's water maze (MWM) and passive avoidance (PA) tests were performed. At the end of the third week, brain tissues were obtained. Histopathological analysis, immunohistochemistry, and electron microscopic examinations were done. The improvement performance of the STZ group was significantly reduced in the MWM test (p < 0.001). Compared with the STZ, STZ-thalidomide, STZ-etanercept, and STZ-infliximab groups had significantly better performance (p < 0.001. <0.05 and <0.05, respectively) in the MWM test. STZ administration caused a significant decrease in the mean escape latency in PA reflex (p < 0.001). Thalidomide, Etanercept, and Infliximab were associated with better PA reflexes compared to the STZ group (p < 0.001 for all). Morphological and immunohistochemical results showed increased neurodegenerative changes compared to sham group. Our findings are in line with the findings reported in the literature and encourage further studies with TNF-alpha antagonists, in particular Thalidomide. (C) 2015 Elsevier GmbH. All rights reserved.
dc.language.isoeng
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectTemel Bilimler
dc.subjectTemel Tıp Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectHistoloji-Embriyoloji
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectHÜCRE BİYOLOJİSİ
dc.titleEffects of systemic Thalidomide and intracerebroventricular Etanercept and Infliximab administration in a Streptozotocin induced dementia model in rats
dc.typeMakale
dc.relation.journalACTA HISTOCHEMICA
dc.contributor.departmentMarmara Üniversitesi , Eczacılık Fakültesi , Eczacılık Meslek Bilimleri Bölümü
dc.identifier.volume117
dc.identifier.issue2
dc.identifier.startpage176
dc.identifier.endpage181
dc.contributor.firstauthorID33989


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record